








Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	10/698,079	
				Filing Date	October 29, 2003	
				First Named Inventor	Cynthia B. Robinson	
				Art Unit	1617	
				Examiner Name	Kevin J. Capps	
Sheet	1	Of	3	Attorney Docket Number		30775-716.201

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 2002/0032160	03/14/2002	Nyce	
	2.	US 2004/0067920	04/08/2004	Leonard et al.	
	3.	US 2004/0082522	04/29/2004	Nyce	
	4.	US 2005/0101545	05/12/2005	Robinson et al.	
	5.	US 4,501,729	02/26/1985	Boucher et al.	
	6.	US 4,956,355	09/11/1990	Prendergast	
	7.	US 6,635,629	10/21/2003	Raymond et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	8.	EP 429187 B1	01/05/1994	Bourke et al.		
	9.	EP 934745 B1	04/28/2004	Kennedy		
	10.	GB 2240472 A	08/07/1991	Masterson		
	11.	WO 1991/04030	04/04/1991	Daynes et al.		
	12.	WO 1996/25935	08/29/1996	Nyce		

Examiner Signature		Date Considered	7/14/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/698,079
				Filing Date	October 29, 2003
				First Named Inventor	Cynthia B. Robinson
				Art Unit	1617
				Examiner Name	Kevin J. Capps
Sheet	2	Of	3	Attorney Docket Number	30775-716.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
W	13.	CRETICOS, P. S. Managing asthma in adults. Am J Manag Care. 2000; 6(17 Suppl):S940-63.	
	14.	ABOU-GHARBIA, et al. Synthesis of dehydroepiandrosterone sulfatide and 16 alpha-halogenated steroids. J Pharm Sci. 1981; 70(10):1154-7.	
	15.	CLARK, et al. The effects of various methods of sacrifice and of ethanol on adenosine levels in selected areas of rat brain. J Neurosci Methods. 1988; 25(3):243-9.	
	16.	FOLKERS, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990;87(22):8931-4.	
	17.	GREENBERG, et al. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol. 1990; 30(7):596-608.	
	18.	HARTIALA, et al. Testosterone metabolism in dog lung in vitro. Steroids Lipids Res. 1973; 4(1):17-23.	
	19.	ISHIHARA, et al. Gas chromatographic determination of degradation products and stability of dehydroepiandrosterone. Drug Develop. Ind. Pharm. 1979; 5(3):263-275.	
	20.	MERCK Index Monograph No. 7710. 11th Ed. 1989.	
	21.	MILEWICH, et al. Androstenedione metabolism in human lung fibroblasts. J Steroid Biochem. 1986; 24(4):893-7.	
	22.	MILEWICH, et al. Metabolism of androsterone and 5 alpha-androstane-3 alpha,17 beta-diol in human lung tissue and in pulmonary endothelial cells in culture. J Clin Endocrinol Metab. 1985; 60(2):244-50.	

Examiner Signature	<i>[Signature]</i>	Date Considered	9/14/03
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.


3039324_1.DOC
Attorney Docket No. 30775-716.201

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/698,079
				Filing Date	October 29, 2003
				First Named Inventor	Cynthia B. Robinson
				Art Unit	1617
				Examiner Name	Kevin J. Capps
Sheet	3	Of	3	Attorney Docket Number	30775-716.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	23.	MILEWICH, et al. Metabolism of dehydroisoandrosterone and androstenedione by the human-lung in vitro. J Steroid Biochem. 1977; 8(4):277-84.	
	24.	MILEWICH, et al. Metabolism of dehydroisoandrosterone and androstenedione in human-pulmonary endothelial cells in culture. J Clin Endocrinol Metab. 1983; 56(5):930-5.	
	25.	MILEWICH, et al. Testosterone metabolism by human lung tissue. J Steroid Biochem. 1978; 9(1):29-32.	
	26.	MORTENSEN, et al. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue React. 1990;12(3):155-62.	
	27.	PONGRACZ, et al. Capillary gas chromatography of urinary steroids of terbutaline-treated asthmatic children. Chromatographia. 1998; 48(1/2): 163-165.	
	28.	TYCZYNSKI, et al. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. Lancet Oncol. 2003; 4(1):45-55.	

UNPUBLISHED PATENT APPLICATIONS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	29.	LEONARD, et al. US Patent Application No. 10/462,927, entitled "Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof," filed June 17, 2003. (WSGR Reference No. 30775-722.201)	

Examiner Signature		Date Considered	7/19/02
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number

10/698.079

Filing Date

October 29, 2003

First Named Inventor

Cynthia B. Robinson

Art Unit

1617

Examiner Name

San Ming R. Hui

Attorney Docket Number

30775-716.201

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

Date _____

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

02486.0068.NPUS01

APPLICATION NO.

10/698,079

APPLICANT

Cynthia B. Robinson, et al.

FILING DATE

October 29, 2003

GROUP

1646



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ul	1.	3,505,337	Apr. 1970	Zeile et al.			
	2.	4,208,423	Jun. 1980	Pfister			
	3.	4,385,048	May 1983	Mygind et al.			
	4.	4,393,066	Jul. 1983	Garrett et al.			
	5.	4,499,064	Feb. 1985	Shive			
	6.	4,575,498	Mar. 1986	Holmes et al.			
	7.	4,628,052	Dec. 1986	Peat			
	8.	4,920,115	Apr. 1990	Nestler et al.			
	9.	4,931,441	Jun. 1990	Lawrence			
	10.	4,985,443	Jan. 1991	Montes			
	11.	5,021,417	Jun. 1991	Prost			
	12.	5,059,595	Oct. 1991	Le Grazie			
	13.	5,077,284	Dec. 1991	Loria et al.			
	14.	5,110,810	May 1992	Eich et al.			
	15.	5,118,505	Jun. 1992	Költringer			
	16.	5,162,198	Nov. 1992	Eich et al.			
	17.	5,173,488	Dec. 1992	Haeger			
	18.	5,177,076	Jan. 1993	Nijkerk et al.			
	19.	5,266,312	Nov. 1993	Leung et al.			
	20.	5,270,305	Dec. 1993	Palmer			
	21.	5,347,005	Sep. 1994	Mueller et al			
	22.	5,407,684	Apr. 1995	Loria et al.			
	23.	5,407,927	Apr. 1995	Morales et al.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Heftel 7/14/02

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i> PTO FORM 1449	ATTY. DOCKET NO.	APPLICATION NO.
	02486.0068.NPUS01	10/698,079
	APPLICANT	
	Cynthia B. Robinson, et al.	
	FILING DATE	GROUP
	October 29, 2003	1646

24.	5,489,581	Feb. 1996	Daynes et al.				
25.	5,527,789	Jun. 1996	Nyce				
26.	5,532,230	Jul. 1996	Daynes et al.				
27.	5,538,734	Jul. 1996	Le Grazie				
28.	5,583,126	Dec. 1996	Daynes et al.				
29.	5,603,918	Feb. 1997	McNamara				
30.	5,635,496	Jun. 1997	Daynes et al.				
31.	5,660,835	Aug. 1997	Nyce				
32.	5,686,438	Nov. 1997	Daynes et al.				
33.	5,703,063	Dec. 1997	Chasalow, et al.				
34.	5,767,278	Jun. 1998	Gaeta et al.				
35.	5,811,418	Sep. 1998	Daynes et al.				
36.	5,859,000	Jan. 1999	Dowell et al.				
37.	5,861,391	Jan. 1999	Yen et al.				
38.	5,948,434	Sep. 1999	Labrie				
39.	5,955,058	Sep. 1999	Jager et al.				
40.	6,087,351	Jul. 2000	Nyce				
41.	6,093,706	Jul. 2000	Zeligs				
42.	6,299,861	Oct. 2001	Banholzer et al.				
43.	6,455,028	Sep. 2002	Wulffhart et al.				
44.	6,455,524	Sep. 2002	Bozung et al.				
45.	2002/0042401	Apr. 2002	Ferguson et al.				
46.	2003/0013772	Jan. 2003	Murphy et al.				
47.	2003/0138434	Jul. 2003	Campbell et al.				
48.	2003/0139331	Jul. 2003	Martin et al.				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i> PTO FORM 1449	ATTY. DOCKET NO.	APPLICATION NO.
	02486.0068.NPUS01	10/698,079
	APPLICANT Cynthia B. Robinson, et al.	
	FILING DATE	GROUP
	October 29, 2003	1646

FOREIGN PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	49. <input checked="" type="checkbox"/>	EP 0 418 716 B1		Europe				
	50. <input checked="" type="checkbox"/>	WO 93/16704		PCT				
	51. <input checked="" type="checkbox"/>	WO 96/16680		PCT				
	52. <input checked="" type="checkbox"/>	WO 97/48367		PCT				
	53. <input checked="" type="checkbox"/>	WO 98/03180		PCT				
	54. <input checked="" type="checkbox"/>	WO 00/54763		PCT				
	55. <input checked="" type="checkbox"/>	WO 01/015745		PCT				
	56. <input checked="" type="checkbox"/>	WO 02/069955		PCT				
	57. <input checked="" type="checkbox"/>	WO 02/85296		PCT				
	58. <input checked="" type="checkbox"/>	WO 03/072572		PCT				
	59. <input checked="" type="checkbox"/>	WO 04/014293 A2		PCT				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
	60. <input checked="" type="checkbox"/>	Araneo et al., "Dehydroepiandrosterone Reduces Progressive Dermal Ischemia Caused by Thermal Injury", J. Surg. Res. 59(2):250-62 (1995).						
	61. <input checked="" type="checkbox"/>	Bonnett et al., "Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension," PNAS 100(16):9488-93 (2003).						
	62. <input checked="" type="checkbox"/>	Budavari, The Merck Index 11 th ed., 1989, pp. 660-661, monograph 4141.						
	63. <input checked="" type="checkbox"/>	Coleridge et al., "Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators", Aust. N.Z. J. Med. 23:348-54 (1993).						
	64. <input checked="" type="checkbox"/>	Dashtaki et al., "Dehydroepiandrosterone and Analogs Inhibit DNA Binding of AP-1 and Airway Smooth Muscle Proliferation", J. Pharmacol. Exp. Ther. 285(2):876-83 (1998).						
	65. <input checked="" type="checkbox"/>	Dompeling et al., "Treatment with Inhaled Steroids in Asthma and Chronic Bronchitis: Long Term Compliance and Inhaler Technique", Family Practice 9(2):161-6 (1992).						
	66. <input checked="" type="checkbox"/>	Dunn, et al., "Dehydroepiandrosterone sulphate concentrations in asthmatic patients: pilot study," N.Z. J. Med. 97(768):805-8 (1984).						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

No Received Doc

<p align="center">LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p> <p align="center">PTO FORM 1449</p>	ATTY. DOCKET NO. 02486.0068.NPUS01	APPLICATION NO. 10/698,079
	APPLICANT Cynthia B. Robinson, et al.	
	FILING DATE October 29, 2003	GROUP 1646

67.	<input checked="" type="checkbox"/>	Duplantier, et al., Novel pharmacological approaches to the treatment of asthma: status and potential of therapeutic classes", <i>DDT</i> 1(5):199-207 (1996)
68.	<input checked="" type="checkbox"/>	Dworski et al., "Conspectus: Inhaled Steroids in Asthma", <i>Comprehensive Therapy</i> , 18:3 (1992).
69.	<input checked="" type="checkbox"/>	Fehér et al., "Adrenocortical Function in Bronchial Asthma", <i>Acta Medica Hungarica</i> 40(2-3):125-32 (1983).
70.	<input checked="" type="checkbox"/>	Fehér, et al., " Dehydroepiandrosterone Therapy of Patients with Corticosteroid Dependent Bronchial Asthma," <i>Natl. Institute of Rheumatism and Physiotherapy, in XIII Congress of the European Academy of Allergology and Clinical Immunology</i> , eds. (Saba, et al., Debrecen Hungary (1986).
71.	<input checked="" type="checkbox"/>	Hampf et al., "Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats," <i>J. Eur. Respir.</i> 21:862-5 (2003).
72.	<input checked="" type="checkbox"/>	Holzmann et al., "Therapy of Psoriasis with Dehydroepiandrosterone-Enanthate. II. Intramuscular Depot Application of 300 mg", <i>Arch. Dermatol. Forsch.</i> 247(1):23-8 (1973) (German with English Abstract).
73.	<input checked="" type="checkbox"/>	Hummel et al., "Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma", <i>The Lancet</i> , 340(8834/8835):1483-7 (1992).
74.	<input checked="" type="checkbox"/>	Inn, "Treatment of COPD Bronchodilator Muscarinic Antagonist", <i>Drugs of the Future</i> 25(7):693-9 (2000)
75.	<input checked="" type="checkbox"/>	Itagaki et al., "Effect of Cortisol on the Release of Human Decidual", <i>Caplus</i> , 114875 (1991) (Japanese with English Abstract).
76.	<input checked="" type="checkbox"/>	Koó et al., "Our experiences with Dehydroepiandrosterone Therapy in Steroid-Dependent Intrinsic Bronchial Asthma", <i>Orvosi Hetilap</i> 128(38):1995-7 (1987) (Hungarian).
77.	<input checked="" type="checkbox"/>	Koó et al., " Our experiences with Dehydroepiandrosterone Therapy in Steroid-Dependent Intrinsic Bronchial Asthma ", <i>Orvosi Hetilap</i> 128(38):1995-7 (1987) (English translation).
78.	<input checked="" type="checkbox"/>	Lejeune, "Pathogenesis of Mental Impairment in Trisomy 21", <i>Annales de Génétique</i> , 92:27643 (1996) (French with English Abstract).
79.	<input checked="" type="checkbox"/>	Mileva et al., "Androstenedione, DHEA sulfate, cortisol, aldosterone and testosterone in bronchial asthma patients", 07608054 (1990) (Russian with English Abstract).
80.	<input checked="" type="checkbox"/>	Nakagawa, et al., "The Properties of Water of Crystallization of Sodium Prasterone Sulfate," <i>Chem. Pharm. Bull</i> 29(5):1466-9 (1981)
81.	<input checked="" type="checkbox"/>	Nakagawa, et al., "The Grinding and Drying on the Solid State Stability of Sodium Prasterone Sulfate," <i>Chem. Pharm. Bull</i> 30(1):242-8 (1982)

DOC NOT RECEIVED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449	ATTY. DOCKET NO. 02486.0068.NPUS01	APPLICATION NO. 10/698,079
	APPLICANT Cynthia B. Robinson, et al.	
	FILING DATE October 29, 2003	GROUP 1646

<input checked="" type="checkbox"/>	82. X	Pashko <i>et al.</i> , "Inhibition of 7,12-dimethylbenz(a)anthracene-induced Skin Papillomas and Carcinomas by Dehydroepiandrosterone and 3-beta-methylandro-5-en-17-one in mice", <i>Cancer Res.</i> 45(1):164-6 (1985).
<input checked="" type="checkbox"/>	83. X	Peeters <i>et al.</i> , "Differences in Purine Metabolism in Patients with Down's Syndrome", <i>J. Intellect. Disabil. Res.</i> 37:471 (1993). Abstract.
<input checked="" type="checkbox"/>	84. X	Reed, "Aerosol Steroids as Primary Treatment of Mild Asthma", <i>New England J. Med.</i> , 325(6):425-6 (1991).
<input checked="" type="checkbox"/>	85. X	Rowe <i>et al.</i> , "Effectiveness of Steroid Therapy in Acute Exacerbations of Asthma: A Meta-analysis", <i>Amer. J. Emergency Med.</i> , 10(4):301-10 (1992).
<input checked="" type="checkbox"/>	86. X	Sasaki <i>et al.</i> , "Cervical Ripening with Dehydroepiandrosterone Sulphate", <i>Br. J. Obstet. Gynaecol.</i> 89(3):195-8, (1982).
<input checked="" type="checkbox"/>	87. X	Sciarra <i>et al.</i> , "Aerosols", Remington's Pharmaceutical Sciences, 18 th ed. (1990), Eds. Gennaro <i>et al.</i> , pp. 1873-5 and 1694-1712.
<input checked="" type="checkbox"/>	88. X	Sharma <i>et al.</i> , "Screening of potential chemopreventive agents using biochemical markers of carcinogenesis", <i>Cancer Res.</i> 54(22):5848-55 (1994).
<input checked="" type="checkbox"/>	89. X	Shomali, "The Use of Anti-Aging Hormones. Melatonin. Growth Hormone, Testosterone, and Dehydroepiandrosterone: Consumer Enthusiasm for Unproven Therapies", <i>Md. Med. J.</i> 46(4):181-6 (1997).
<input checked="" type="checkbox"/>	90. X	Sonka <i>et al.</i> , "Gout and Dehydroepiandrosterone: 3. DHEA Administration", <i>Endokrynologia Polska</i> 24(3):209-18 (1973).
<input checked="" type="checkbox"/>	91. X	Sur <i>et al.</i> , "Double-blind trial pyroxidine (vitamin B6) in the treatment of steroid-dependent asthma", <i>Ann. Allergy</i> , 70:147-52 (1993).
<input checked="" type="checkbox"/>	92. X	Schwartz <i>et al.</i> , "Inhibition of 7,12-dimethylbenz[a]anthracene- and urethan-induced lung tumor formation in A/J mice by long-term treatment with dehydroepiandrosterone," <i>Carcinogenesis</i> 2(12):1335-7 (1981)
<input checked="" type="checkbox"/>	93. X	Van de Graaf <i>et al.</i> , "Respiratory Membrane Permeability and Bronchial Hyperreactivity in Patients with Stable Asthma: Effects of Therapy with Inhaled Steroids", <i>Bronchial Asthma and Respiratory Membrane Permeability</i> 143:362-8 (1991).
<input checked="" type="checkbox"/>	94. X	Van Vollenhoven <i>et al.</i> , "Dehydroepiandrosterone in SLE. Results of a Double-Blind, Placebo-Controlled, Randomized Clinical Trial.", <i>Arthritis Rheum.</i> 38(12): 1826-31 (1995).
<input checked="" type="checkbox"/>	95. X	Wolkowitz <i>et al.</i> , "Dehydroepiandrosterone Treatment of Depression", <i>Biol. Psychiatry</i> 41(3):311-8. (1997).

DOC RECEIVED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NOT considered ; DOCs NOT recd.